Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Tafamidis Free Acid Tablets vs Capsule in Healthy Adults
NCT06273839Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM) (6 arms), sponsored by Pfizer. Primary endpoints: Area under the concentration-time curve from time zero to infinity at 168 hours and Maximum observed plasma concentration at 168 hours. Started Feb 2024; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06273839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273839.